The T‐cell fingerprint of MALT 1 paracaspase revealed by selective inhibition
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Mucosa‐associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is essential for immune responses triggered by antigen receptors but the contribution of its paracaspase activity is not fully understood. Here, we studied how MALT 1 proteolytic function regulates T‐cell activation and fate after engagement of the T‐cell receptor pathway. We show that MLT‐827, a potent and selective MALT 1 paracaspase inhibitor, does not prevent the initial phase of T‐cell activation, in contrast to the pan‐protein kinase C inhibitor AEB 071. However, MLT‐827 strongly impacted cell expansion after activation. We demonstrate this is the consequence of profound inhibition of IL‐2 production as well as reduced expression of the IL‐2 receptor alpha subunit (CD 25), resulting from defective canonical NF‐κB activation and accelerated mRNA turnover mechanisms. Accordingly, MLT‐827 revealed a unique transcriptional fingerprint of MALT 1 protease activity, providing evidence for broad control of T‐cell signaling pathways. Altogether, this first report with a potent and selective inhibitor elucidates how MALT 1 paracaspase activity integrates several T‐cell activation pathways and indirectly controls gamma‐chain receptor dependent survival, to impact on T‐cell expansion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Ashkenazi, A., Fairbrother, W. J., Leverson, J. D., & Souers, A. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.253 · Cited by 903
CD28-mediated co-stimulation: a quantitative support for TCR signalling.
Acuto, O., & Michel, F. (2003) · Nature Reviews Immunology · doi:10.1038/nri1248 · Cited by 775 · cited 2×
“After TCR pathway engagement, several markers become detectable at the plasma membrane and their expression level can be read out as a measure of T-cell activation.(31) Pan-protein kinase C inhibition by AEB071 abolished induced surface expression of CD25 (IL2Ra), CD69, OX40 and ICOS in response to a range of anti-CD3…”
BackgroundCARMA1, BCL-10 and MALT1 in lymphocyte development and activation
Thome, M. (2004) · Nature Reviews Immunology · doi:10.1038/nri1352 · Cited by 391
Mino, T., Murakawa, Y., Fukao, A., Vandenbon, A., Wessels, H.-H., Ori, D., Uehata, T., Tartey, S., Akira, S., Suzuki, Y., et al. (2015) · Cell · doi:10.1016/j.cell.2015.04.029 · Cited by 390
Jeltsch, K. M., Hu, D., Brenner, S., Zöller, J., Heinz, G. A., Nagel, D., Vogel, K. U., Rehage, N., Warth, S. C., Edelmann, S. L., et al. (2014) · Nature Immunology · doi:10.1038/ni.3008 · Cited by 274
Cited by
Germinal center‐derived lymphomas: The darkest side of humoral immunity
Mlynarczyk, C., Fontán, L., & Melnick, A. (2019) · Immunological Reviews · doi:10.1111/imr.12755 · Cited by 179
Quancard, J., Klein, T., Fung, S.-Y., Renatus, M., Hughes, N., Israël, L., Priatel, J. J., Kang, S., Blank, M. A., Viner, R. I., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-018-0222-1 · Cited by 72
Self-citationIsraël, L., Bardet, M., Huppertz, A., Mercado, N., Ginster, S., Unterreiner, A., Schlierf, A., Goetschy, J. F., Zerwes, H.-G., Roth, L., et al. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.03.1503 · Cited by 18
Self-citation
Metadata
- Authors
- Bardet, M., Unterreiner, A., Malinverni, C., Lafossas, F., Vedrine, C., Boesch, D., Kolb, Y., Kaiser, D., Glück, A., Schneider, M. A., Katopodis, A., Renatus, M., Simic, O., Schlapbach, A., Quancard, J., Régnier, C. H., Bold, G., Pissot‐Soldermann, C., Carballido, J. M., Kovarik, J., Calzascia, T., & Bornancin, F.
- Venue
- Immunology & Cell Biology
- Publisher
- Wiley
- Published
- 2017-12-21
- Volume
- 96
- Issue
- 1
- Pages
- 81-99
- ISSN
- 0004-945X (ISSN-L)
- 0818-9641
- 1440-1711
- OpenAlex
- W2784186865
- Cited by
- 60
- References
- 5
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.